Zezhe Pharmaceutical disclosure 2022 semi -annual report achieved revenue of 105 million yuan

On August 18th, A -share listed company Zeye Pharmaceutical (Code: 688266.SH) released the semi -annual performance report in 2022.

From January 1, 2022 to June 30, 2022, the company realized operating income of 105 million yuan, an increase of 148.53%year-on-year, a net loss of 247 million yuan, and the loss of 39.58%year-on-year losses, and the basic earnings per share were -1.03 yuan.

The company's industry is chemical pharmaceutical.

During the company's reporting period, the total assets at the end of the period were 1.625 billion yuan, the operating profit was -264 million yuan, and the accounts receivable was 36.751 million yuan. The net cash flow generated by operating activities was -159 million yuan.The cash was 146 million yuan.

Zezhe Pharmaceutical, the company's full name Suzhou Zezhe Biopharmaceutical Co., Ltd., was established on March 18, 2009. The current general manager Sheng Zelin.Innovative -driven chemistry and new biological drug development and production in multiple treatment areas.

- END -